title: Efficacy of swine influenza A virus vaccines against an H3N2 virus variant.
abstract: We compared the efficacy of 3 commercial vaccines against swine influenza A virus (SIV) and an experimental homologous vaccine in young pigs that were subsequently challenged with a variant H3N2 SIV, A/Swine/Colorado/00294/2004, selected from a repository of serologically and genetically characterized H3N2 SIV isolates obtained from recent cases of swine respiratory disease. The experimental vaccine was prepared from the challenge virus. Four groups of 8 pigs each were vaccinated intramuscularly at both 4 and 6 wk of age with commercial or homologous vaccine. Two weeks after the 2nd vaccination, those 32 pigs and 8 nonvaccinated pigs were inoculated with the challenge virus by the deep intranasal route. Another 4 pigs served as nonvaccinated, nonchallenged controls. The serum antibody responses differed markedly between groups. After the 1st vaccination, the recipients of the homologous vaccine had hemagglutination inhibition (HI) titers of 1:640 to 1:2560 against the challenge (homologous) virus. In contrast, even after 2nd vaccination, the commercial-vaccine recipients had low titers or no detectable antibody against the challenge (heterologous) virus. After the 2nd vaccination, all the groups had high titers of antibody to the reference H3N2 virus A/Swine/Texas/4199-2/98. Vaccination reduced clinical signs and lung lesion scores; however, virus was isolated 1 to 5 d after challenge from the nasal swabs of most of the pigs vaccinated with a commercial product but from none of the pigs vaccinated with the experimental product. The efficacy of the commercial vaccines may need to be improved to provide sufficient protection against emerging H3N2 variants.
authors: Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, 385 Animal Science/Veterinary Medicine Building, 1988 Fitch Avenue, St. Paul, Minnesota 55108, USA.
authors: Jee Hoon
authors: JH
authors: Lee
authors: Marie René
authors: MR
authors: Gramer
authors: Han Soo
authors: HS
authors: Joo
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D006385:Hemagglutination Inhibition Tests / Q000662:veterinary; D007114:Immunization / Q000662:veterinary; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D007273:Injections, Intramuscular / Q000662:veterinary; D009296:Nasal Cavity; D009976:Orthomyxoviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D011897:Random Allocation; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control*
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines
references: Arch Virol. 1991;116(1-4):261-5
references: 1848066
references: Vet Pathol. 1995 Nov;32(6):648-60
references: 8592800
references: Can J Vet Res. 1996 Oct;60(4):312-4
references: 8904668
references: Vet Microbiol. 2000 May 22;74(1-2):47-58
references: 10799777
references: Virus Res. 2000 Jun;68(1):71-85
references: 10930664
references: J Virol. 2000 Sep;74(18):8243-51
references: 10954521
references: Arch Virol. 2000;145(7):1399-419
references: 10963345
references: Vaccine. 2001 Aug 14;19(31):4479-86
references: 11483274
references: Vet Immunol Immunopathol. 2001 Sep 28;82(1-2):39-56
references: 11557293
references: J Clin Microbiol. 2002 Mar;40(3):1073-9
references: 11880444
references: J Virol Methods. 2002 Apr;102(1-2):53-9
references: 11879692
references: J Vet Diagn Invest. 2002 Mar;14(2):169-71
references: 11939342
references: Virus Res. 2002 May 10;85(2):199-210
references: 12034486
references: Vaccine. 2003 Mar 28;21(13-14):1375-81
references: 12615433
references: J Clin Microbiol. 2003 Jul;41(7):3198-205
references: 12843064
references: Can Vet J. 2003 Sep;44(9):735-7
references: 14524628
references: Virus Res. 2004 Jul;103(1-2):67-73
references: 15163491
references: Vaccine. 2004 Sep 3;22(25-26):3427-34
references: 15308368
references: J Clin Microbiol. 1979 Feb;9(2):175-9
references: 219021